###begin article-title 0
uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180
###end article-title 0
###begin p 1
###xml 43 67 43 67 <email xmlns:xlink="http://www.w3.org/1999/xlink">Chris.Marshall@icr.ac.uk</email>
Correspondence to Christopher J. Marshall: Chris.Marshall@icr.ac.uk
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 387 388 384 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The urokinase-type plasminogen activator receptor (uPAR) drives tumor cell membrane protrusion and motility through activation of Rac; however, the pathway leading from uPAR to Rac activation has not been described. In this study we identify DOCK180 as the guanine nucleotide exchange factor acting downstream of uPAR. We show that uPAR cooperates with integrin complexes containing beta3 integrin to drive formation of the p130Cas-CrkII signaling complex and activation of Rac, resulting in a Rac-driven elongated-mesenchymal morphology, cell motility, and invasion. Our findings identify a signaling pathway underlying the morphological changes and increased cell motility associated with uPAR expression.
###end p 3
###begin p 4
###xml 159 164 <span type="species:ncbi:9606">human</span>
Abbreviations used in this paper: ERK, extracellular signal-regulated kinase; GEF, guanine nucleotide exchange factor; GPI, glycosylphosphatidylinositol; HEK, human embryonic kidney; MEK, MAPK/ERK kinase; SD, substrate domain; uPAR, urokinase-type plasminogen activator receptor.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 151 174 151 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Memarzadeh et al., 2002</xref>
###xml 176 195 176 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Kaneko et al., 2003</xref>
###xml 197 217 197 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">El-Kott et al., 2004</xref>
###xml 219 242 219 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib63">Salajegheh et al., 2005</xref>
###xml 244 261 244 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">Meng et al., 2006</xref>
###xml 278 295 278 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Bene et al., 2004</xref>
###xml 457 478 457 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">Pedersen et al., 1993</xref>
###xml 480 497 480 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">Pyke et al., 1993</xref>
###xml 499 524 499 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Blasi and Carmeliet, 2002</xref>
###xml 738 754 738 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Liu et al., 2002</xref>
###xml 756 778 756 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">Chaurasia et al., 2006</xref>
###xml 780 795 780 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Jo et al., 2006</xref>
###xml 850 874 850 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib62">Saksela and Rifkin, 1990</xref>
###xml 876 893 876 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib64">Sato et al., 1990</xref>
###xml 895 915 895 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib59">Ribatti et al., 1999</xref>
###xml 975 994 975 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">Aguirre-Ghiso, 2007</xref>
###xml 1163 1180 1163 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib71">Vial et al., 2003</xref>
###xml 1182 1201 1182 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">Lester et al., 2007</xref>
###xml 1203 1222 1203 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Madsen et al., 2007</xref>
###xml 82 87 <span type="species:ncbi:9606">human</span>
The urokinase-type plasminogen activator receptor (uPAR) is overexpressed in many human cancers, its expression often correlating with poor prognosis (Memarzadeh et al., 2002; Kaneko et al., 2003; El-Kott et al., 2004; Salajegheh et al., 2005; Meng et al., 2006; for review see Bene et al., 2004). It is expressed as a glycosylphosphatidylinositol (GPI)-anchored plasma membrane protein and in a soluble form that is secreted or shed from the cell surface (Pedersen et al., 1993; Pyke et al., 1993; Blasi and Carmeliet, 2002). Through binding to its ligands, the protease uPA and the extracellular matrix glycoprotein vitronectin, uPAR may be involved in several processes related to tumor progression, including growth factor signaling (Liu et al., 2002; Chaurasia et al., 2006; Jo et al., 2006), release of sequestered growth factors from the ECM (Saksela and Rifkin, 1990; Sato et al., 1990; Ribatti et al., 1999), and reemergence from tumor cell dormancy (for review see Aguirre-Ghiso, 2007). Importantly, expression of uPAR is associated with the acquisition of a motile, invasive tumor cell phenotype, a process thought to be crucial for cancer metastasis (Vial et al., 2003; Lester et al., 2007; Madsen et al., 2007).
###end p 6
###begin p 7
###xml 184 209 184 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Blasi and Carmeliet, 2002</xref>
###xml 211 228 211 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Dano et al., 2005</xref>
###xml 542 564 542 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Kjoller and Hall, 2001</xref>
###xml 566 583 566 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib71">Vial et al., 2003</xref>
###xml 679 701 679 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Kjoller and Hall, 2001</xref>
###xml 703 718 703 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">Jo et al., 2003</xref>
###xml 845 860 845 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">Ma et al., 2002</xref>
###xml 862 879 862 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib71">Vial et al., 2003</xref>
###xml 977 999 977 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Kjoller and Hall, 2001</xref>
###xml 1001 1016 1001 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">Ma et al., 2002</xref>
###xml 1018 1037 1018 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Madsen et al., 2007</xref>
###xml 1141 1162 1141 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib67">Sidenius et al., 2002</xref>
###xml 1164 1183 1164 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Madsen et al., 2007</xref>
###xml 1361 1380 1361 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">Llinas et al., 2005</xref>
###xml 1382 1401 1382 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Madsen et al., 2007</xref>
GPI-anchored uPAR localizes to the leading edge of migrating cells, and complexes of uPA-uPAR are thought to promote cell motility by activating the plasminogen system to degrade ECM (Blasi and Carmeliet, 2002; Dano et al., 2005). In addition to its roles in the regulation of pericellular proteolysis, a large body of evidence has identified uPAR as a signaling receptor that activates intracellular pathways. Activation of the Rho family small GTPase Rac has emerged as an important event in the promotion of motility and invasion by uPAR (Kjoller and Hall, 2001; Vial et al., 2003). Ectopic uPAR expression results in Rac-dependent lamellipodial protrusion and cell motility (Kjoller and Hall, 2001; Jo et al., 2003), and inhibiting endogenous uPAR expression inactivates Rac and strongly inhibits lamellipodial protrusion and cell motility (Ma et al., 2002; Vial et al., 2003). Rac activation by uPAR can occur in the absence of uPA, but depends on binding to vitronectin (Kjoller and Hall, 2001; Ma et al., 2002; Madsen et al., 2007). However, uPA binding may contribute to signaling by increasing the affinity of uPAR for vitronectin (Sidenius et al., 2002; Madsen et al., 2007). Because the vitronectin-binding site is located on the opposite side of the molecule from the uPA-binding cleft, multimeric complexes containing all three molecules may form (Llinas et al., 2005; Madsen et al., 2007).
###end p 7
###begin p 8
###xml 209 229 209 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Resnati et al., 2002</xref>
###xml 246 263 246 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Bass et al., 2005</xref>
###xml 316 335 316 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">Czekay et al., 2001</xref>
###xml 358 379 358 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Behrendt et al., 2000</xref>
###xml 590 609 590 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Aguirre Ghiso, 2002</xref>
###xml 611 629 611 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib82">Zhang et al., 2003</xref>
###xml 631 647 631 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib77">Wei et al., 2007</xref>
###xml 757 775 757 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib68">Simon et al., 1996</xref>
###xml 805 806 801 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 810 811 803 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 821 822 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 826 827 812 813 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 829 845 815 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib75">Wei et al., 2001</xref>
###xml 847 863 833 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib76">Wei et al., 2005</xref>
###xml 897 898 879 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 902 903 881 882 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 913 914 888 889 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 918 919 890 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 921 942 893 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Carriero et al., 1999</xref>
###xml 944 964 916 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Degryse et al., 2005</xref>
###xml 1092 1108 1064 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib80">Xue et al., 1997</xref>
###xml 1196 1212 1168 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib76">Wei et al., 2005</xref>
###xml 1390 1409 1362 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Madsen et al., 2007</xref>
Being GPI anchored and lacking transmembrane and cytoplasmic domains, uPAR relies on transmembrane coreceptors for intracellular signaling. Potential coreceptors for uPAR include G protein- coupled receptors (Resnati et al., 2002), tetraspanins (Bass et al., 2005), low density lipoprotein receptor-related protein (Czekay et al., 2001), and Endo180/UPARAP (Behrendt et al., 2000). In particular, several studies suggest that integrins are involved in uPAR signaling. Expression of uPAR results in integrin-associated signaling events such as phosphorylation of FAK and Src family kinases (Aguirre Ghiso, 2002; Zhang et al., 2003; Wei et al., 2007). uPAR-integrin interactions have been shown by coimmunoprecipitation of uPAR with leukocyte integrin Mac-1 (Simon et al., 1996), fibronectin receptors alpha3beta1 and alpha5beta1 (Wei et al., 2001; Wei et al., 2005), and vitronectin receptors alphavbeta3 and alphavbeta5 (Carriero et al., 1999; Degryse et al., 2005). The formation of these uPAR-integrin interactions may depend both on integrin subunit expression and composition of the ECM (Xue et al., 1997). Association of uPAR with integrins has been proposed to alter integrin conformation (Wei et al., 2005). However, the existence of direct uPAR-integrin binding remains controversial, as a recent study has shown that the putative integrin-binding residues in uPAR are dispensable (Madsen et al., 2007). These authors proposed that uPAR interacts indirectly with integrins by increasing cell matrix adhesion through uPAR-vitronectin binding, therefore facilitating integrin binding to ligands.
###end p 8
###begin p 9
###xml 277 292 277 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">Bos et.al. 2007</xref>
###xml 396 416 396 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Jaffe and Hall, 2005</xref>
Of particular interest in the context of cell motility is how uPAR signals to Rac activation. Cycling of small GTPases between active GTP-bound and inactive GDP-bound forms is regulated by guanine nucleotide exchange factors (GEFs), which catalyze the exchange of GDP for GTP (Bos et.al. 2007), and GTPase activating proteins (GAPs), which stimulate the intrinsic GTPase activity (for review see Jaffe and Hall, 2005). Because many studies link uPAR to integrin signaling, we used a candidate approach to identify integrin-associated GEFs that might be required for Rac activation in uPAR-expressing cell lines. These studies identified DOCK180 as the GEF involved in uPAR-mediated Rac activation. We then investigated how uPAR influences signaling to DOCK180.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
DOCK180 is required for uPAR-driven Rac activation and invasion
###end title 11
###begin p 12
###xml 326 347 319 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Kiyokawa et al., 1998</xref>
###xml 349 368 342 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">Moores et al., 2000</xref>
###xml 370 399 363 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">Marignani and Carpenter, 2001</xref>
###xml 401 420 394 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">Matsuo et al., 2003</xref>
###xml 422 446 415 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib60">Rosenberger et al., 2003</xref>
###xml 448 467 441 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Arthur et al., 2004</xref>
###xml 469 489 462 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Gakidis et al., 2004</xref>
###xml 491 510 484 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Faccio et al., 2005</xref>
###xml 512 533 505 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Hamelers et al., 2005</xref>
###xml 876 884 865 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 1000 1017 989 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib71">Vial et al., 2003</xref>
###xml 1368 1376 1357 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
Because uPAR may signal together with integrins, we examined the role of GEFs that have been linked to integrin signaling to identify GEFs that may function downstream of uPAR. A literature search identified alpha-PIX, beta-PIX, DOCK180, Sos1, Tiam1, Tiam2, Vav1, Vav2, and Vav3 as potential Rac GEFs downstream of integrins (Kiyokawa et al., 1998; Moores et al., 2000; Marignani and Carpenter, 2001; Matsuo et al., 2003; Rosenberger et al., 2003; Arthur et al., 2004; Gakidis et al., 2004; Faccio et al., 2005; Hamelers et al., 2005). We used RNAi to silence expression of these GEFs (apart from alpha-PIX, Vav1, and Vav3 for which no expression was detected) in the colon carcinoma cell line BE. BE cells endogenously express uPAR and exhibit a bipolar mesenchymal morphology with abundant membrane ruffling and lamellipodia shown by phalloidin staining to be F-actin rich (Fig. 1 A). This characteristic morphology, together with extensive random migration, is abrogated by silencing uPAR or Rac (Vial et al., 2003). We used this easily scorable phenotype to search for GEFs whose silencing mimicked the effects of silencing uPAR. DOCK180 was the only GEF for which silencing resulted in similar effects to abrogating uPAR expression, resulting in flattening, loss of ruffles and lamellipodia, more pronounced cortical actin staining, and occasional stress fibers (Fig. 1 A and Fig. S1 A, available at ).
###end p 12
###begin p 13
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DOCK180 is required for uPAR-driven membrane ruffling and Rac activation.</bold>
###xml 697 698 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 751 752 750 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
DOCK180 is required for uPAR-driven membrane ruffling and Rac activation. (A) BE colon carcinoma cells transfected with indicated siRNAs were plated on vitronectin-coated coverslips for 12 h, fixed, and stained with Texas red-conjugated phalloidin. Bar, 50 mum. (B and C) HEK 293T cells were transfected with siRNAs targeting DOCK180 or nontargeting control (NT), and 48 h later were transfected with uPAR expression vector or empty vector control. After 24 h, Rac-GTP pull-down assays were performed. (B) Representative immunoblots to show pull-down assay, uPAR expression, and DOCK180 silencing. (C) Rac activation was quantitated and analyzed as described in Materials and methods (mean + SEM; n = 3). *, P < 0.05; **, P < 0.01; unpaired Student's t test.
###end p 13
###begin p 14
###xml 239 254 239 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 421 436 421 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 89 94 <span type="species:ncbi:9606">human</span>
To show that uPAR signals through DOCK180 to activate Rac, we used ectopic expression in human embryonic kidney (HEK) 293T cells that lack endogenous uPAR. Transfection with a uPAR expression construct activates Rac approximately twofold (Fig. 1, B and C). Strikingly, this stimulation was lost when uPAR was expressed in HEK 293T cells in which DOCK180 expression had been abrogated with either of two different siRNAs (Fig. 1, B and C). Significantly, in empty vector controls, DOCK180 silencing had no effect on Rac activity, showing basal Rac activity in HEK 293T cells does not require DOCK180. Therefore, in this system DOCK180 is required for uPAR-driven Rac activation rather than basal levels of Rac activity.
###end p 14
###begin p 15
###xml 249 267 249 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">Mohan et al., 1999</xref>
###xml 269 288 269 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib69">Sturge et al., 2002</xref>
###xml 290 307 290 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib71">Vial et al., 2003</xref>
###xml 595 603 595 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 749 757 737 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
To examine whether DOCK180 is required for Rac activation in tumor cell lines expressing uPAR, we used BE, MDA-MB-231 breast carcinoma cells, and SNB19 glioblastoma cells in which endogenous uPAR signaling is required for cell motility or invasion (Mohan et al., 1999; Sturge et al., 2002; Vial et al., 2003). We silenced DOCK180 expression in these cell lines using a panel of siRNA oligonucleotides, including an ON-TARGET SMART pool that incorporates technology designed to reduce "off-target" effects. Each siRNA treatment abrogating DOCK180 expression significantly reduced Rac activation (Fig. 2 A). The degree of inhibition of Rac activation resulting from silencing DOCK180 was very similar to that from silencing uPAR (approximately50-60%; Fig. 2 A). As well as reducing Rac activation, siRNA treatments against either DOCK180 or uPAR elicited similar morphological changes in the three cell lines with reduced membrane ruffling and lamellipodial protrusion (Fig. S1 B and not depicted), demonstrating that the effects are a true consequence of silencing these genes rather than a nonspecific or off-target effect.
###end p 15
###begin p 16
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DOCK180 is required for Rac activation and invasion in uPAR-expressing tumor cell lines.</bold>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 366 367 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 642 643 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 698 699 694 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
DOCK180 is required for Rac activation and invasion in uPAR-expressing tumor cell lines. (A) BE (closed bars), MDA-MB-231 (open bars), and SNB19 (shaded bars) cells were transfected with siRNAs. NT, nontargeting control; NT-OT, ON-TARGET nontargeting control. Rac activity was quantitated at 72 h (mean + SEM; n >/= 3). *, P < 0.05; **, P < 0.01; unpaired Student's t test. (inset) Representative immunoblots from one Rac pull down in BE cells. Irrelevant lanes were removed (represented by vertical black lines). (B) BE (closed bars) and MDA-MB-231 (open bars) cells transfected with siRNAs were assayed for collagen-I invasion (mean + SEM; n >/= 3). *, P < 0.05; **, P < 0.01; unpaired Student's t test. Immunoblots showing knockdown are in Fig. S2 A, available at .
###end p 16
###begin p 17
###xml 71 88 71 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib71">Vial et al., 2003</xref>
###xml 228 236 228 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
Because uPAR-driven Rac activation has been shown to promote invasion (Vial et al., 2003), BE and MDA-MB-231 cells were assayed for invasion of a three-dimensional collagen matrix in response to a chemotactic gradient of serum. Fig. 2 B shows that in both cell lines silencing DOCK180 or uPAR inhibited invasion to a comparable degree (40-50%). Confirming that loss of Rac reduced cell motility, time-lapse phase-contrast microscopy revealed a severe defect in random cell motility when DOCK180 or uPAR was silenced (Videos 1-3 [BE], available at ; and not depicted for MDA-MB-231 and SNB19).
###end p 17
###begin p 18
These studies show that in an ectopic uPAR expression system and in three different tumor cell lines expressing endogenous uPAR, silencing DOCK180 results in reduced Rac activation. This suggests that uPAR signals through DOCK180 for uPAR-driven Rac activation and membrane protrusion, resulting in cell motility and invasion.
###end p 18
###begin title 19
uPAR drives tyrosine phosphorylation of p130Cas and formation of the Cas-Crk complex
###end title 19
###begin p 20
###xml 360 380 360 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">Matsuda et al., 1996</xref>
###xml 495 513 495 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib61">Sakai et al., 1994</xref>
###xml 604 625 604 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">Polte and Hanks, 1995</xref>
###xml 909 917 897 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 1094 1102 1082 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 1278 1296 1266 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib72">Vuori et al., 1996</xref>
###xml 1346 1364 1334 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib82">Zhang et al., 2003</xref>
Because uPAR signals through DOCK180 to activate Rac, the roles of known upstream regulators of DOCK180 were examined to characterize the pathway linking uPAR and DOCK180. The regulation of DOCK180 by integrin signaling involves protein-protein interactions where the N-terminal SH3 domain of the adaptor protein Crk binds to a proline-rich region in DOCK180 (Matsuda et al., 1996) and the SH2 domain of Crk binds to phosphotyrosine residues in the substrate domain (SD) of the adaptor p130Cas (Sakai et al., 1994). The p130Cas-Crk-DOCK180 module associates with integrins via binding of p130Cas to FAK (Polte and Hanks, 1995). To investigate whether uPAR influences p130Cas SD tyrosine phosphorylation and recruitment of Crk, we first examined the effects of ectopic uPAR expression in HEK 293T cells. Expression of uPAR results in an approximately50% increase in tyrosine phosphorylation of the p130Cas SD (Fig. 3 A). Increased tyrosine phosphorylation of p130Cas was associated with a dramatic induction of the p130Cas-Crk complex, as determined by coimmunoprecipitation of Crk and p130Cas (Fig. 3 B). These results show that ectopic expression of uPAR drives formation of the p130Cas-Crk complex. As the p130Cas SD has been shown to be phosphorylated by Src family kinases (Vuori et al., 1996), and as uPAR has been linked to c-Src activity (Zhang et al., 2003), we investigated whether uPAR-dependent Rac activation required c-Src activity. Ectopic expression of uPAR in HEK 293T cells led to increased c-Src phosphorylation on the Y416 activation site and treatment with the Src inhibitors PP1 or PP2 or the structurally unrelated SU6656 blocked Rac activation, whereas PP3, the inactive stereoisomer of PP2, had no effect (Fig. S3 A, available at ).
###end p 20
###begin p 21
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">uPAR expression drives p130Cas SD phosphorylation and formation of the p130Cas&#8211;CrkII complex.</bold>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 714 715 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 768 769 768 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 973 974 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1029 1030 1027 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
uPAR expression drives p130Cas SD phosphorylation and formation of the p130Cas-CrkII complex. (A) p130Cas SD tyrosine phosphorylation in uPAR- or vector-transfected (Vec) HEK 293T cells. Left, representative immunoblots; right, quantitation of SD phosphorylation (mean + SEM; n = 3). (B) p130Cas-Crk complex formation in uPAR- or empty vector-transfected HEK 293T cells. Left, representative immunoblots; right, immunoblot showing expression of p130Cas, uPAR, and GAPDH. (C) p130Cas SD tyrosine phosphorylation in siRNA-transfected cells. Top left, representative immunoblots (BE); top right, uPAR immunoblotting; bottom, quantitation. Closed bars, BE; open bars, MDA-MB-231; shaded bars, SNB19 cells (mean + SEM; n = 4). *, P < 0.05; **, P < 0.01; unpaired Student's t test. (D) Analysis of p130Cas-Crk complex formation. Left, representative immunoblots (BE); right, quantitation. Closed bars, BE cells; open bars, MDA-MB-231 cells; shaded bars, SNB19 cells (mean + SEM; n >/= 4). *, P < 0.05; **, P < 0.01; unpaired Student's t test.
###end p 21
###begin p 22
###xml 276 284 276 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 486 494 486 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
To examine whether endogenously expressed uPAR signals through p130Cas and Crk, we silenced uPAR expression in the tumor cell lines. Silencing uPAR with each of three different siRNA oligonucleotides reduced p130Cas SD tyrosine phosphorylation by up to 40% in each cell line (Fig. 3 C). Similar results were observed in SNB19 and MDA-MB-231 cells (unpublished data). In all three tumor cell lines, the formation of the p130Cas-Crk complex was also strongly inhibited by silencing uPAR (Fig. 3 D).
###end p 22
###begin p 23
###xml 246 261 246 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, A and B</xref>
###xml 291 306 291 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 761 769 749 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
To confirm that p130Cas and Crk are required for uPAR signaling to Rac activation, we used the ectopic uPAR expression system. Silencing p130Cas or Crk abrogated the 2-2.5-fold stimulation of Rac-GTP loading on uPAR expression in HEK 293T cells (Fig. 4, A and B). As with DOCK180 silencing (Fig. 1, B and C), silencing p130Cas or Crk did not affect basal Rac-GTP loading, demonstrating the specific role of p130Cas and Crk in uPAR signaling to Rac. Consistent with the findings from the ectopic expression studies, silencing the expression of either adaptor using three different siRNA oligonucleotides, including ON-TARGET SMART pools, in the endogenous uPAR-expressing tumor cell lines BE and SNB19 resulted in approximately50-60% inhibition of Rac activity (Fig. 5 A).
###end p 23
###begin p 24
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">p130Cas and Crk are required for uPAR-stimulated Rac activation in HEK 293T cells.</bold>
###xml 421 422 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
p130Cas and Crk are required for uPAR-stimulated Rac activation in HEK 293T cells. HEK 293T cells were transfected with siRNAs. 48 h after siRNA transfection cells were transfected with uPAR expression vector or empty vector control (Vec). 24 h later (72 h after siRNA transfection), Rac pull-down assays were performed. (A) Representative immunoblots from one experiment. (B) Quantitation of Rac activation (mean + SEM; n = 3). *, P < 0.05; **, P < 0.01; unpaired Student's t test. (C) Representative immunoblots of silencing p130Cas and CrkII at 72 h after transfection.
###end p 24
###begin p 25
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">p130Cas and Crk are required for Rac activation and invasion in uPAR-expressing tumor cell lines.</bold>
###xml 236 242 236 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 256 257 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 299 300 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 667 668 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 723 724 719 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
p130Cas and Crk are required for Rac activation and invasion in uPAR-expressing tumor cell lines. (A) BE cells (closed bars) and SNB19 cells (shaded bars) were transfected with siRNAs, and Rac activation was quantitated as described in Fig. 2 (mean + SEM; n >/= 5). **, P < 0.01; unpaired Student's t test. (B) BE cells were transfected with siRNAs, and the association of p130Cas with DOCK180 was determined by immunoprecipitation of DOCK180 and immunoblotting for p130Cas. Immunoblots are representative of three independent experiments. (C) BE cells were transfected with siRNAs. At 60 h after transfection, cells were assayed for collagen-I invasion (mean + SEM; n >/= 4). *, P < 0.05; **, P < 0.01; unpaired Student's t test. Immunoblots showing knockdown are in Fig. S2 B, available at .
###end p 25
###begin p 26
###xml 315 323 315 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 599 628 599 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib70">Tosello-Trampont et al., 2007</xref>
These results argue that uPAR activates Rac through driving the formation of p130Cas-Crk complexes that could potentially recruit DOCK180 through association with Crk. To confirm that signaling through uPAR can recruit DOCK180 to complexes containing p130Cas, we immunoprecipitated DOCK180 and blotted for p130Cas. Fig. 5 B shows that in BE cells, p130Cas and DOCK180 coimmunoprecipitate but the amount of this complex is reduced when uPAR is silenced. This indicates that DOCK180 and the adaptor proteins p130Cas and Crk are in the same pathway downstream of uPAR rather than in separate pathways (Tosello-Trampont et al., 2007).
###end p 26
###begin p 27
###xml 217 225 217 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 369 377 357 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 392 400 380 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 446 461 434 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, A and B</xref>
To demonstrate that p130Cas-Crk complex signaling to Rac contributes to tumor cell invasion, we studied whether abrogating expression of p130Cas or Crk affects BE cell invasion of a three-dimensional collagen matrix. Fig. 5 C shows that silencing p130Cas or Crk inhibited invasion by approximately40-50%. Silencing p130Cas or Crk has similar effects on Rac activation (Fig. 1 C) or invasion (Fig. 2 B) to when either uPAR or DOCK180 is silenced (Fig. 2, A and B).
###end p 27
###begin title 28
###xml 20 21 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Requirement for beta3 integrin in uPAR-driven Rac activation
###end title 28
###begin p 29
###xml 354 375 354 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Kiyokawa et al., 1998</xref>
###xml 467 468 463 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 472 473 465 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 480 481 469 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 485 486 471 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 496 497 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 512 520 495 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 D</xref>
###xml 615 636 598 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Carriero et al., 1999</xref>
###xml 638 658 621 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Degryse et al., 2005</xref>
###xml 660 682 643 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">Chaurasia et al., 2006</xref>
###xml 742 743 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 747 748 723 724 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 758 759 730 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 763 764 732 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1143 1144 1106 1107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1204 1205 1164 1165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1269 1270 1226 1227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1304 1305 1258 1259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1493 1494 1444 1445 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1595 1596 1543 1544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
Our data show that uPAR expression drives tyrosine phosphorylation of the p130Cas SD, promoting the formation of the p130Cas-Crk complex that recruits DOCK180. This leads to Rac activation and acquisition of a motile, invasive phenotype in tumor cell lines. Because the p130Cas-Crk-DOCK180 pathway is known to be activated by integrin-mediated adhesion (Kiyokawa et al., 1998), we investigated which integrins are involved. BE, MDA-M231, and SNB19 cells express alphavbeta3, alphavbeta5, and beta1 integrin (see Fig. 7 D; Fig. S5 D, available at ; and not depicted), which have been reported to interact with uPAR (Carriero et al., 1999; Degryse et al., 2005; Chaurasia et al., 2006). Blocking antibody and siRNA experiments showed that alphavbeta3 and alphavbeta5, but not uPAR, are required for adhesion to vitronectin (Fig. S5, A-C). To investigate the involvement of integrins in uPAR signaling to Rac activation, beta integrin subunits were silenced using panels of siRNA oligonucleotides consisting of two individual oligonucleotide duplexes and one ON-TARGET SMART pool for each target (ITGB1#1, ITGB1#2, and ITGB1 OT for targeting beta1 integrin; ITGB3#1, ITGB3#2, and ITGB3 OT for targeting beta3 integrin; and ITGB5#1, ITGB5#2, and ITGB5 OT for targeting beta5 integrin). Only silencing of beta3 integrin mimicked the phenotype of uPAR or DOCK180 silencing in BE cells (Fig. S4, A and B). Similar effects were observed in MDA-MB-231 and SNB19 cells (unpublished data). Silencing beta1 integrin resulted in loss of polarity and delocalization of membrane ruffling whereas silencing beta5 resulted in defects in adhesion and rear retraction (Fig. S4, A and B).
###end p 29
###begin p 30
###xml 47 48 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 70 71 64 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 142 150 136 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 227 228 218 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 311 312 299 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 452 453 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 457 458 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 492 515 473 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">Cheresh and Spiro, 1987</xref>
###xml 554 555 532 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 682 683 657 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Rac pull-down assays showed that silencing beta3 integrin but not beta1 integrin in BE, MDA-MB-231, and SNB19 cells decreased Rac activation (Fig. 6 A). Consistent with the lack of an effect on membrane ruffling, silencing beta5 integrin had no effect on Rac activation (Fig. S4 C). The effect of silencing beta3 integrin is very similar in magnitude to that observed when uPAR, DOCK180, Crk, or p130Cas is silenced. Consistent with the fact that alphavbeta3 is a major vitronectin receptor (Cheresh and Spiro, 1987), we found that silencing uPAR or beta3 integrin only affected Rac activity in BE cells plated on vitronectin and not on collagen or fibronectin, which are major beta1 integrin ligands (Fig. S5 E). Similarly, ectopic expression of uPAR in HEK 293T cells led to Rac activation if the cells were plated in serum-free medium on vitronectin or in serum as a source of vitronectin, but there was no Rac activation if the cells were plated in serum-free medium on fibronectin or collagen-1 (Fig. S5 F).
###end p 30
###begin p 31
###xml 4 5 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 71 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#946;<sub>3</sub> integrin is required for Rac activation in uPAR-expressing cells.</bold>
###xml 225 226 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 281 282 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 421 422 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 477 478 470 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 630 631 623 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 673 674 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 896 897 887 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 938 939 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
beta3 integrin is required for Rac activation in uPAR-expressing cells. (A) Tumor cells were transfected with siRNAs and Rac activation was quantitated. Closed bars, BE; open bars, MDA-MB-231; shaded bars, SNB19 (mean + SEM; n >/= 4). *, P < 0.05; **, P < 0.01; unpaired Student's t test. (B) BE (closed bars) and MDA-MB-231 cells (open bars) were transfected with siRNAs and assayed for collagen-I invasion (mean + SEM; n >/= 4). *, P < 0.05; **, P < 0.01; unpaired Student's t test. (C) BE cells were seeded for invasion assays in serum-free DME or DME + 5% serum and either control IgG or antivitronectin antibody (mean + SEM; n >/= 4). **, P < 0.01; unpaired Student's t test. (D) HEK 293T cells were transfected with siRNAs, and after 48 h, transfected with uPAR or empty vector. Rac activity was measured 24 h later. (E) Quantitation of Rac-activation assays in HEK 293T cells (mean + SEM; n >/= 5). *, P < 0.05; unpaired Student's t test versus nontargeting. Immunoblots showing knockdown are in Fig. S2 (C and D), available at .
###end p 31
###begin p 32
###xml 43 44 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 53 54 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 114 115 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 125 126 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 215 223 203 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 273 274 258 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 499 519 472 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib81">Zanetti et al., 1994</xref>
###xml 555 563 528 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 742 743 712 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 914 915 869 870 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1018 1042 973 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">Pollard and Borisy, 2003</xref>
The contributions of signaling through beta1 and beta3 integrin subunits to invasion were examined by testing beta1- and beta3-silenced BE and MDA-MB-231 cells for invasion of a three-dimensional collagen-1 matrix (Fig. 6 B). In both BE and MDA-MB-231 cells, silencing beta3 integrin inhibited invasion by approximately40%. Invasion in these assays was dependent on vitronectin present in serum as no invasion took place in the absence of serum, and the addition of a vitronectin-blocking antibody (Zanetti et al., 1994) blocked serum-dependent invasion (Fig. 6 C). This was consistent with the observed effects on invasion of silencing uPAR, DOCK180, Crk, and p130Cas in these cells. Although it did not affect Rac activation, silencing beta1 integrin decreased invasion by approximately90% in BE cells and 40-50% in MDA-MB-231 cells. This is not unexpected because all collagen-binding integrins contain the beta1 subunit, and adhesion to the substratum is essential for the elongated/mesenchymal mode of migration (Pollard and Borisy, 2003).
###end p 32
###begin p 33
###xml 27 28 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 145 161 142 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 (D and E)</xref>
###xml 187 188 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 273 274 264 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 394 395 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 399 400 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 548 556 532 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 688 689 669 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 700 718 681 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib78">Woods et al., 2001</xref>
###xml 782 783 760 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 795 821 773 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Aguirre Ghiso et al., 1999</xref>
###xml 848 849 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 933 934 905 906 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 936 944 908 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 970 971 939 940 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1108 1109 1073 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1113 1114 1075 1076 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1165 1166 1124 1125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1188 1189 1144 1145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1287 1288 1240 1241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1301 1302 1251 1252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1313 1321 1263 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 1366 1367 1313 1314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1434 1435 1377 1378 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1439 1440 1379 1380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1568 1576 1508 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 C</xref>
###xml 1630 1631 1567 1568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1705 1706 1638 1639 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1710 1711 1640 1641 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1769 1770 1696 1697 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1848 1849 1772 1773 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1908 1909 1829 1830 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2002 2003 1920 1921 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2014 2022 1932 1940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
To investigate whether beta3 integrin was required for uPAR-driven Rac activation in HEK 293T cells, integrin subunits were silenced with siRNA; Fig. 6 (D and E) shows that silencing beta3 in HEK 293T cells blocked Rac activation. However, unlike the tumor cell lines, beta1 silencing did reduce Rac activation in uPAR-transfected HEK 293T cells. Significantly, flow cytometry showed that alphavbeta3 was not expressed at the surface of control or empty vector-transfected HEK 293T cells but was expressed at the surface of uPAR-transfected cells (Fig. 7 A). Previous work has shown that sustained extracellular signal-regulated kinase (ERK) activation leads to surface expression of beta3 integrin (Woods et al., 2001), and as uPAR-mediated ERK activation has been shown to be beta1 dependent (Aguirre Ghiso et al., 1999), we examined whether beta1 integrin expression and ERK activation were required for surface expression of beta3. Fig. 7 A shows that silencing beta1 integrin or treatment with the MAPK/ERK kinase (MEK) inhibitors PD184352 or UO126 (unpublished data) blocked surface expression of alphavbeta3 in uPAR-transfected HEK 293T cells. Silencing beta1 integrin but not beta3 integrin blocked uPAR-dependent ERK activation, showing that ERK activation by uPAR requires beta1 but not beta3 integrin (Fig. 7 B). Consistent with the observations that beta1 integrin signals to ERK activation and surface expression of alphavbeta3, inhibition of ERK activation with MEK inhibitors PD184352 or UO126 blocked Rac activation in uPAR-transfected HEK 293T cells (Fig. 7 C). These results show that signaling via uPAR and beta1 integrins to ERK activation can provide the surface localization of alphavbeta3 required for uPAR-dependent Rac activation. Although beta1 integrin-dependent ERK activation was required for surface expression of beta3 integrin, immunoblotting showed that uPAR expression, beta1 integrin knockdown, or inhibition of ERK activation did not affect total cell levels of beta3 integrin (Fig. 7 A).
###end p 33
###begin p 34
###xml 44 45 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 86 87 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 122 0 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cooperation between uPAR signaling with &#946;<sub>1</sub> integrin to ERK-MAPK activation and &#946;<sub>3</sub> integrin&#8211;dependent Rac activation.</bold>
###xml 159 160 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 164 165 151 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 351 352 333 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 356 357 335 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 395 396 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 400 401 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 428 429 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 599 600 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 639 640 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 788 789 757 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 828 829 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 867 868 832 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 872 873 834 835 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1177 1178 1139 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Cooperation between uPAR signaling with beta1 integrin to ERK-MAPK activation and beta3 integrin-dependent Rac activation. (A) Cell surface expression of alphavbeta3 in uPAR- or vector-transfected HEK 293T cells. Top three left panels, siRNA-transfected cells; top right panel, 2 muM PD184352 or vehicle (DMSO) treatment. Red, IgG control; blue, alphavbeta3 vector transfected; green, uPAR-alphavbeta3 transfected. (bottom) beta3 integrin immunoblot of siRNA-transfected or PD184352-treated HEK 293T cells. (B) HEK 293T cells were transfected as in A and ERK1/2 activation was measured (mean + SEM; n = 6). *, P < 0.05; unpaired Student's t test. (C) Rac activation in HEK 293T cells transfected with uPAR or vector and treated with MEK inhibitors or vehicle (DMSO) for 24 h (mean + SEM; n = 6). *, P < 0.05; unpaired Student's t test. (D) Surface expression of alphavbeta3 on BE cells. Left and middle, siRNA transfections; right, MEK inhibition. Data are representative of three independent experiments. (E) ERK1/2 activation in cells transfected with siRNAs. Left, representative immunoblot (BE), total ERK1/2 (red), phospho-ERK1/2 (green); right, quantitation (mean + SEM; n = 4). Closed bars, BE cells; open bars, MDA-MB-231; shaded bars, SNB19.
###end p 34
###begin p 35
###xml 43 44 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 140 141 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 145 146 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 157 165 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 D</xref>
###xml 204 205 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 209 210 192 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 291 299 274 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 D</xref>
###xml 356 357 336 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 404 412 384 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 E</xref>
###xml 492 509 472 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib71">Vial et al., 2003</xref>
###xml 578 579 555 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 660 661 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 665 666 635 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 723 724 690 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 794 795 757 758 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 799 800 759 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
In contrast to HEK 293T cells, uPAR or beta1 integrin silencing in BE colon carcinoma cells did not affect the surface localization of alphavbeta3 integrin (Fig. 7 D); however, surface expression of alphavbeta3 integrin in BE, MDA-MB231, and SNB19 was partially dependent on ERK activation (Fig. 7 D and Fig. S5 D). In none of the tumor cell lines was beta1 integrin or uPAR required for ERK activation (Fig. 7 E). BE and MDA-MB231 harbor activating mutations in KRAS and BRAF or KRAS alone (Vial et al., 2003) that presumably uncouple ERK activation from a requirement for beta1 integrin and uPAR. These results therefore argue that uPAR signals through alphavbeta3 for Rac activation, but that uPAR signaling through beta1 integrins can provide an ERK signal for surface localization of alphavbeta3.
###end p 35
###begin title 36
###xml 4 5 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
beta3 integrin is required for p130Cas SD tyrosine phosphorylation and formation of the p130Cas-CrkII complex
###end title 36
###begin p 37
###xml 12 13 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 311 312 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 423 431 414 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 460 461 448 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 656 657 641 642 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 693 694 675 676 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 719 727 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 801 802 780 781 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1004 1005 980 981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1143 1144 1116 1117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1273 1281 1246 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 1351 1352 1321 1322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1484 1485 1451 1452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1539 1540 1503 1504 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1610 1611 1571 1572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1701 1702 1659 1660 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1713 1721 1671 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 E</xref>
Because beta3 integrin-silenced cells had defects in morphology, Rac activation, and invasion similar to those observed in cells where components of the uPAR-DOCK180 pathway had been silenced, we examined the roles of beta integrin subunits in signaling through the p130Cas-CrkII adaptor complex. Silencing beta3 integrin in BE, MDA-MB231, and SNB19 tumor cells strongly reduced tyrosine phosphorylation of the p130Cas SD (Fig. 8 A). Conversely, silencing beta1 integrin did not affect p130Cas SD phosphorylation. In keeping with the p130Cas SD tyrosine phosphorylation data, coimmunoprecipitation of p130Cas with CrkII was also inhibited by silencing beta3 integrin, whereas silencing of beta1 integrin had no effect (Fig. 8 B). These data show that expression of uPAR promotes signaling through beta3 integrin to drive tyrosine phosphorylation of the p130Cas SD and formation of the p130Cas-CrkII adaptor complex. Consistent with the requirement for Src in Rac activation driven by uPAR, silencing beta3 integrin blocked Src activation driven by uPAR (Fig. S3, B and D) but did not affect FAK Y397 phosphorylation (Fig. S3 C). Silencing beta3 integrin also abrogated the stimulation of p130Cas SD tyrosine phosphorylation by ectopically expressed uPAR in HEK 293T cells (Fig. 8 C). However, as observed for uPAR-driven Rac activation, silencing beta1 integrin in HEK 293T cells also abrogated uPAR-driven p130Cas SD tyrosine phosphorylation. This is consistent with the role of beta1 integrin in promoting cell surface expression of beta3 integrin by cooperating with uPAR to activate ERK, a function of beta1 integrin that is not required in the tumor cells where ERK activity does not require beta1 integrin (Fig. 7 E).
###end p 37
###begin p 38
###xml 4 5 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 110 0 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#946;<sub>3</sub> integrin is required for p130Cas SD tyrosine phosphorylation and formation of the p130Cas&#8211;CrkII complex.</bold>
###xml 250 251 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 304 305 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 552 553 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 592 593 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 809 815 806 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 829 830 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 869 870 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
beta3 integrin is required for p130Cas SD tyrosine phosphorylation and formation of the p130Cas-CrkII complex. (A) p130Cas SD tyrosine phosphorylation in siRNA-transfected cells. Left, representative immunoblot (BE); right, quantitation (mean + SEM; n = 5). *, P < 0.05; **, P < 0.01; unpaired Student's t test. Closed bars, BE; open bars, MDA-MB-231; shaded bars, SNB19. Irrelevant lanes were removed (represented by vertical black lines). (B) Analysis of p130Cas-Crk complexes. Left, representative immunoblots (BE); right, quantitation (mean + SEM; n = 4). *, P < 0.05; unpaired Student's t test. Closed bars, BE; open bars, MDA-MB-231; shaded bars, SNB19. (C) Analysis of p130Cas SD tyrosine phosphorylation in HEK 293T cells transfected with siRNAs and uPAR or empty vector was performed as described in Fig. 3 (mean + SEM; n = 4). *, P < 0.05; unpaired Student's t test. Immunoblots showing knockdown are in Fig. S2 E, available at .
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 265 284 265 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">Klemke et al., 1998</xref>
###xml 392 410 392 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">Nolan et al., 1998</xref>
###xml 412 432 412 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib79">Wu and Horvitz, 1998</xref>
###xml 434 452 434 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">Moore et al., 2007</xref>
###xml 679 700 679 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">Gumienny et al., 2001</xref>
###xml 702 723 702 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Brugnera et al., 2002</xref>
In this study we have identified a mechanism of Rac activation by uPAR. We show for the first time that in both ectopic and endogenous systems uPAR expression results in activation of Rac via the GEF DOCK180. DOCK180 has been shown to have a role in cell motility (Klemke et al., 1998) and developmental processes such as myoblast fusion, dorsal closure, and phagocytosis of apoptotic cells (Nolan et al., 1998; Wu and Horvitz, 1998; Moore et al., 2007). Our data show that uPAR signaling to DOCK180 results in the induction of tumor cell motility and invasion. In several systems, ELMO has been linked to DOCK180 function possibly through acting as a cofactor for GEF activity (Gumienny et al., 2001; Brugnera et al., 2002). Whether it is involved in uPAR-driven Rac activation will be an interesting topic for future investigation.
###end p 40
###begin p 41
###xml 664 685 664 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Kjoller and Hall 2001</xref>
###xml 727 743 727 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib74">Wei et al., 1994</xref>
Having identified DOCK180 as a Rac GEF regulated by uPAR, we examined how DOCK180 is activated downstream of uPAR. Previous work in other systems shows that integrin signaling recruits DOCK180 to the plasma membrane via the formation of a p130Cas-Crk-DOCK180 complex. Key to the formation of this complex is tyrosine phosphorylation of the p130Cas SD that recruits Crk-DOCK180 complexes via the SH2 domain of Crk. We show that uPAR, expressed endogenously by tumor cells or ectopically in HEK 293T cells, drives the tyrosine phosphorylation of the p130Cas SD and formation of the p130Cas-Crk complex. For Rac activation by uPAR, uPA does not seem to be essential (Kjoller and Hall 2001) and is not expressed by HEK 293T cells (Wei et al., 1994). However, uPA-uPAR interactions may play an important role in other systems or in tumor cell invasion in vivo, whether by enhancing uPAR binding to vitronectin or through mechanisms such as focused ECM proteolysis at the leading edge or enhancing local availability of growth factors. Consistent with uPAR signaling through the p130Cas-Crk complex, we find that p130Cas and Crk are required for Rac activation by uPAR and for the invasion of uPAR-expressing tumor cells.
###end p 41
###begin p 42
###xml 130 150 130 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">Auvinen et al., 1995</xref>
###xml 152 172 152 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">Nievers et al., 1997</xref>
###xml 174 192 174 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Honda et al., 1998</xref>
###xml 194 213 194 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">Kirsch et al., 2002</xref>
###xml 215 234 215 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Cabodi et al., 2006</xref>
###xml 453 472 453 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">Klemke et al., 1998</xref>
###xml 625 648 625 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Bershadsky et al., 2006</xref>
###xml 872 891 872 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib65">Sawada et al., 2006</xref>
p130Cas is a multifunctional adaptor protein required for embryonic development and oncogenic signal transduction in tumor cells (Auvinen et al., 1995; Nievers et al., 1997; Honda et al., 1998; Kirsch et al., 2002; Cabodi et al., 2006). It is also an important regulator of cell migration, and in particular its association with Crk constitutes a molecular switch vital for cell motility by recruiting DOCK180 to integrin-containing adhesion complexes (Klemke et al., 1998). These complexes also serve a mechanosensory function allowing the cell to sense the physical properties, such as rigidity, of the ECM (for review see Bershadsky et al., 2006). Interestingly, in vitro data suggests that p130Cas can function as a transducer of mechanical signals, with the SD adopting an extended conformation permissive for phosphorylation in response to increased physical force (Sawada et al., 2006). This could promote Rac-driven migration in response to physical cues in the extracellular environment. As we have shown that uPAR stimulates the tyrosine phosphorylation of the p130Cas SD, the role of uPAR in integrin-mediated mechanotransduction is an interesting subject for future investigation. In addition, it is well known that p130Cas and Crk can interact with other partners besides DOCK180. Therefore, promotion of p130Cas SD tyrosine phosphorylation and p130Cas-CrkII complex assembly by uPAR may regulate a variety of other signaling pathways.
###end p 42
###begin p 43
###xml 441 442 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 455 456 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 548 549 539 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 565 566 553 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 660 661 645 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 785 786 766 767 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 790 791 768 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 822 823 797 798 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 887 888 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 892 893 860 861 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 920 921 884 885 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 925 926 886 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 989 990 947 948 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1078 1079 1033 1034 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
The identification of DOCK180, an integrin-associated GEF, in uPAR-Rac signaling is in keeping with a large body of evidence implicating integrins as the signaling partners of uPAR. A relatively large array of integrin heterodimers have been shown to interact with uPAR, but whether any of these are specifically required for uPAR to activate Rac in tumor cells had not been previously investigated. In the tumor cell lines we examined, beta3 but not beta1 integrin was required for uPAR-DOCK180 signaling to Rac activation. In HEK 293T cells, beta1 as well as beta3 integrin are required for uPAR-stimulated Rac activation, but in these cells the role of beta1 integrin appears to be to provide the ERK activation (Aguirre-Ghiso et al., 1999) necessary for surface expression of alphavbeta3. Thus, in some cells uPAR-beta1 integrin signaling to ERK-dependent surface expression of alphavbeta3 cooperates with uPAR-alphavbeta3 signaling for Rac activation, whereas in other cells uPAR-beta3 integrin drives Rac activation but ERK activation does not seem to require uPAR or beta1 integrin signaling.
###end p 43
###begin p 44
###xml 347 369 347 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Kjoller and Hall, 2001</xref>
###xml 371 390 371 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Madsen et al., 2007</xref>
###xml 425 426 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 634 655 630 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib66">Schvartz et al., 1999</xref>
###xml 968 969 961 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Several papers have emphasized the importance of vitronectin in membrane protrusion and cell motility induced by uPAR expression, and both integrin signaling and direct binding of uPAR to vitronectin were recently shown to be required for stimulation of membrane ruffling and lamellipodial protrusion by ectopic uPAR expression in HEK 293T cells (Kjoller and Hall, 2001; Madsen et al., 2007). We have shown that uPAR and beta3 integrin are required for Rac activation in tumor cells cultured on vitronectin or in the presence of serum, which is an abundant source of vitronectin with concentrations in the range of 200 to 400 mug/ml (Schvartz et al., 1999). In the collagen-1-based three-dimensional invasion assay we have used, a function-blocking antivitronectin antibody inhibits serum-stimulated invasion, demonstrating that invasion is dependent on vitronectin. Consistent with its role in uPAR-driven Rac activation in the presence of vitronectin, silencing beta3 integrin expression also inhibits serum-stimulated invasion.
###end p 44
###begin p 45
###xml 37 38 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 479 499 476 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Madsen et al. (2007)</xref>
###xml 757 758 751 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1277 1294 1271 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib73">Wei et al. (2008)</xref>
###xml 1365 1366 1356 1357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1399 1415 1390 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib73">Wei et al., 2008</xref>
###xml 1384 1390 <span type="species:ncbi:10090">murine</span>
These data suggest that uPAR and beta3 integrin engage vitronectin to promote Rac activity and tumor cell invasion. The nature of uPAR-integrin interactions is controversial. Although many studies have shown uPAR-integrin coimmunoprecipitation, this does not prove the existence of direct binding. Immunoprecipitation under gentle conditions may result in the detection of many proteins associated with detergent-resistant lipid rafts, including uPAR and integrins. The study of Madsen et al. (2007) has cast doubt on the role of specific uPAR residues in mediating binding to integrins, although it does not rule out direct interactions involving multiple residues over a large binding surface. Our data are consistent with a model where both uPAR and beta3 integrin coordinately engage vitronectin. This could affect signaling in several ways, for example, by facilitation of integrin-ligand interaction, effects on integrin clustering, or modification of integrin conformation by lateral uPAR-integrin interactions. Interestingly, silencing uPAR expression or blocking uPAR function using an antibody that recognizes the vitronectin-binding site had no effect on the adhesion of tumor cells to vitronectin (Fig. S5, A-C). Significantly, while this paper was in preparation, Wei et al. (2008) have demonstrated that uPAR expression leads to the activation of beta3 integrins in the murine kidney (Wei et al., 2008).
###end p 45
###begin p 46
###xml 38 39 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 241 242 235 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 379 403 373 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Etienne-Manneville, 2004</xref>
###xml 518 539 512 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">del Pozo et al., 2004</xref>
###xml 586 607 580 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Del Pozo et al., 2002</xref>
###xml 614 615 605 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Interestingly, our data show that beta1 integrin silencing causes a severe cell motility phenotype in uPAR-expressing tumor cell lines, without affecting Rac activation but causing a delocalization of membrane ruffling and lamellipodia. beta1 integrin signaling may affect tumor cell polarity, for example, by regulating Cdc42, which is a major regulator of polarized migration (Etienne-Manneville, 2004). Also by inhibiting internalization of lipid rafts, which contain both uPAR and binding sites for activated Rac (del Pozo et al., 2004), and by regulating interactions with RhoGDI (Del Pozo et al., 2002), beta1 integrin may affect spatial control of Rac-driven protrusion and motility.
###end p 46
###begin p 47
###xml 303 308 <span type="species:ncbi:9606">human</span>
Determination of the molecular mechanisms underlying uPAR signaling, such as the Rac activation pathway described here, is essential to provide insight into the well-established role of uPAR in tumor cell invasion. Understanding these pathways will provide new therapeutic targets for the prevention of human tumor metastasis.
###end p 47
###begin title 48
Materials and methods
###end title 48
###begin title 49
Antibodies and reagents
###end title 49
###begin p 50
###xml 152 153 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 172 173 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 237 238 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 271 272 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 311 312 295 296 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 316 317 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 337 338 314 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 342 343 316 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 282 288 <span type="species:ncbi:9986">rabbit</span>
###xml 685 690 <span type="species:ncbi:10090">mouse</span>
###xml 770 775 <span type="species:ncbi:9606">human</span>
###xml 818 824 <span type="species:ncbi:9913">Bovine</span>
The following antibodies were used: anti-Rac1 (clone 23A8; Fitzgerald), anti-uPAR (R&D Systems), anti-GAPDH (Novus Biologicals), anti-DOCK180, anti-beta3integrin, anti-beta1integrin (clone P5D2; Santa Cruz Biotechnology, Inc.), anti-beta1 integrin (clone JB1a), anti-beta3 integrin rabbit polyclonal, anti-alphavbeta3 (LM609), anti-alphavbeta5 (P1F6), antivitronectin (clone BV2; Millipore), anti-p130Cas, anti-Crk, anti-FAK (BD Biosciences), anti-alpha-tubulin, anti-total, phosphoERK (Sigma-Aldrich), anti-p130Cas phosphotyrosine 410 (Cell Signaling Technology), anti-c-Src (clone GD11; Millipore), anti-Src phosphoY416 (Invitrogen), anti-FAK phosphoY397 (Affinity BioReagents), and mouse IgG isotype controls (R&D systems). Vitronectin and fibronectin (purified from human serum) were purchased from Sigma-Aldrich. Bovine Type I collagen solution was purchased from Invitrogen. PD184352 was obtained from C. Springer (Institute of Cancer Research, Sutton, England, UK) and U0126 was obtained from Sigma-Aldrich. PP1, PP2, PP3, and SU6656 were purchased from EMD). Texas red-labeled phalloidin was purchased from Invitrogen. pRcCMV-uPAR was a provided by A. Hall (Memorial Sloan-Kettering Cancer Center, New York, NY). HRP-coupled secondary antibodies were from purchased Sigma-Aldrich and fluorophore-coupled secondary antibodies were purchased from Li-COR Biosciences.
###end p 50
###begin title 51
Cell culture
###end title 51
###begin p 52
###xml 486 487 478 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1307 1308 1296 1297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1365 1366 1351 1352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1423 1424 1406 1407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1486 1487 1466 1467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1546 1547 1523 1524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1606 1607 1580 1581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1669 1670 1640 1641 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1727 1728 1695 1696 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 1785 1786 1750 1751 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
BE colon carcinoma cells were obtained from the Institute of Cancer Research Tissue Resource Laboratory; HEK 293T and MDA-MB-231 breast carcinoma cells from the American Tissue Type Culture Collection; and SNB19 glioblastoma cells from the Deutsche Sammlung von Mikroorganismen und Zellkulturen. All cells were maintained in DME, supplemented with 10% FCS purchased from PAA Laboratories, 100 mug/ml streptomycin, and 60 mug/ml penicillin. Cells were maintained at 37degreesC and 10% CO2. siRNA transfections in tumor cell lines were performed using InterferIN (Polyplus) according to the manufacturer's instructions. The final concentration of siRNA in the transfection was 2 nM. For siRNA transfection of HEK 293T cells, HiPerfect (QIAGEN) was used with 50-nM final concentration of siRNA according to the manufacturer's instructions. Sequences of siRNA oligonucleotides were as follows: DOCK180 #1, CUGACUCAGAACGUGGACC; DOCK180 #2, UAAAUGAGCAGCUGUACAA; DOCK180-OT (Thermo Fisher Scientific); uPAR #1, GAAGAGACUUUCCUCAUUG; uPAR #2, GGUGACGCCUUCAGCAUGA; uPAR #3, GGUGAAGAAGGGCGUCCAA; Crk #1, AAUAGGAGAUCAAGAGUUU; Crk #2, GGACAGCGAAGGCAAGAGA; Crk-OT (Thermo Fisher Scientific); p130Cas #1, GGUCGACAGUGGUGUGUAU; p130Cas #2, AGAAGGAGCUGCUGGAAAA; p130Cas-OT (Thermo Fisher Scientific); ITGB1 #1 (targeting beta1 integrin), GAACAGAUCUGAUGAAUGA; ITGB1 #2 (targeting beta1 integrin), CAAGAGAGCUGAAGACUAU; ITGB1-OT (targeting beta1 integrin; Thermo Fisher Scientific); ITGB3 #1 (targeting beta3 integrin), CUCUCCUGAUGUAGCACUUAA; ITGB3 #2 (targeting beta3 integrin), CACGUGUGGCCUGUUCUUCUA; ITGB3-OT (targeting beta3 integrin; Thermo Fisher Scientific); ITGB5 #1 (targeting beta5 integrin), GAACAACGGUGGAGAUUUU; ITGB5 #2 (targeting beta5 integrin), GGAGGGAGUUUGCAAAGUU; ITGB5-OT (targeting beta5 integrin; Thermo Fisher Scientific). Controls used were AllStars nontargeting control (QIAGEN), ON-TARGET nontargeting control SMART Pool (Thermo Fisher Scientific), and nontargeting control SMART Pool (Thermo Fisher Scientific).
###end p 52
###begin p 53
Transfection of HEK 293T cells with plasmid DNA (6 mug DNA per 10-cm cell culture dish) was performed using GeneJuice (EMD) according to the manufacturer's instructions. Plasmid DNA was prepared using the HiSpeed Plasmid Maxi kit (QIAGEN).
###end p 53
###begin title 54
Microscopy
###end title 54
###begin p 55
Static phase-contrast images were obtained from a microscope camera workstation (Digital Site DS-4; Nikon) attached to an inverted phase-contrast microscope (TS100; Nikon) using a LWD 20x objective (NA 0.4; Nikon) at 21degreesC. Images were processed for contrast and brightness using Photoshop v7.0 (Adobe).
###end p 55
###begin p 56
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Multi-site time-lapse video microscopy was performed in a humidified, CO2-equilibrated chamber at 37degreesC using an inverted phase-contrast microscope (TE2000; Nikon) in conjunction with digital cameras (either Orca-ER or C9100EM-CCD; Hamamatsu Photonics), and equipped with motorized stage, focus, and shutter systems (Prior Scientific Instruments, Ltd.), all controlled by Simple PCI AIC acquisition software (v6.5; Compix Imaging Systems). Cells were imaged using PlanFluor 10x (0.3 NA; Nikon) or PlanFluor ELWD 20x (0.45 NA; Nikon) objectives for at least 24 h at a rate of one frame per site per 4 min. Movies were exported from Simple PCI software as uncompressed AVI files with a frame rate of 15 frames per second. Premiere (v6.0; Adobe) was used to compress movie files using the MPEG codec, which were then converted to MOV (Quicktime) format using iMovie HD with a frame rate of 15 frames per second (dimensions: 640 x 512).
###end p 56
###begin p 57
Confocal sections were obtained with a laser-scanning confocal imaging system (MRC 1024; Bio-Rad Laboratories) mounted on an upright fluorescence microscope (E600; Nikon) with PLan Apo 60x oil immersion objective (NA 1.4) at 21degreesC, and using LaserSharp acquisition software (Bio-Rad Laboratories). Images were exported as PIC files and processed for brightness and contrast using Photoshop, supplemented with PIC file recognition plug-in (Bio-Rad Laboratories).
###end p 57
###begin title 58
Analysis of Rac1 activation
###end title 58
###begin p 59
###xml 89 108 89 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Benard et al., 1999</xref>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 301 302 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 488 489 488 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
A GST fusion of the CRIB domain of PAK1 was used to pull down the activated form of Rac (Benard et al., 1999). The PAK1-CRIB domain GST fusion protein was bound to glutathione-Sepharose beads (GE Healthcare). 5 x 105-106 cells in a 10-cm dish were washed in Rac wash buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT [Sigma-Aldrich], and EDTA-free complete protease inhibitors [Roche]) and lysed on ice for 3 min in ice-cold Rac lysis buffer (50 mM Tris-HCl, 10% glycerol, 1% NP-40, 5 mM MgCl2, 100 mM NaCl, and EDTA-free complete protease inhibitors). Lysates were cleared by centrifugation at 13,200 rpm for 5 min in a centrifuge (5810R; Eppendorff) at 4degreesC and an aliquot was kept for determination of total Rac levels by Western blotting. The remainder of the lysate was incubated with 30-mul PAK-CRIB-Sepharose beads for 45 min on a rotating wheel at 4degreesC. Beads were collected by brief centrifugation and washed three times in 500 mul of ice-cold Rac lysis buffer and resuspended in 20 mul of LDS sample buffer (Invitrogen), and electrophoresis (NOVEX NuPAGE Midi gel system; Invitrogen) was performed with the total volume of each Rac pull down and equivalent volumes of total cell lysate for determination of total Rac. Fluorescent immunoblotting of Rac in pull downs and total lysate used anti-Rac clone 23A8 (Fitzgerald) and the Odyssey (Li-COR Biosciences). Data from the Odyssey were exported into Excel (Microsoft) and the ratio of signals for Rac GTP/Total Rac was calculated for each sample. For tumor cell lines, data are normalized to values from mock-transfected cells. Statistical comparisons for each siRNA were made against the nontargeting control and ON-TARGET SMART Pools were compared with ON-TARGET nontargeting controls. For HEK 293T cells, data are shown as fold stimulation of Rac activation, obtained by dividing the Rac activation in uPAR-transfected cells by that of the vector control for each condition.
###end p 59
###begin title 60
Invasion assay
###end title 60
###begin p 61
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 229 230 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 267 268 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 599 600 585 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 55 61 <span type="species:ncbi:9913">bovine</span>
###xml 176 182 <span type="species:ncbi:9913">bovine</span>
Cells were suspended in 2.3 mg/ml of serum-free liquid bovine collagen at 105 cells/ml. 100-mul aliquots were dispensed into black 96-well ViewPlates (PerkinElmer) coated with bovine serum albumin. Plates were centrifuged at 300 g and incubated in a 37degreesC/10% CO2 tissue culture incubator. Once collagen had polymerized, FCS was added on top of the collagen to a final concentration of 5%. For vitronectin-blocking studies, 20 mug/ml antivitronectin antibody or isotype-matched IgG control were preincubated with FCS for 30 min at room temperature. After 24-h incubation at 37degreesC in 10% CO2, cells were fixed and stained for 2 h in 4% formaldehyde solution (Sigma-Aldrich) containing 5 mug/ml Hoechst 33258 nuclear stain (Invitrogen). Confocal z slices were collected from each well at 50 mum to count invaded cells, and at the bottom (3 mum) to count total cells using a high content microscope (INCELL3000; GE Healthcare) with a 40x PlanFluor ELWD objective (0.6 NA; Nikon). Nuclear staining in each slice was quantified automatically with INCELL3000 Object Intensity module to determine the percentage of invaded cells. Samples were run in quadruplicate and averaged. Data analysis was performed using Excel. Invasion index was calculated at number of cells at 50 mum per total number of cells. Data are presented as a percentage of the invasion index of mock-transfected cells. Statistical comparisons for siRNAs were made against the nontargeting control, and ON-TARGET SMART Pools were compared with ON-TARGET nontargeting controls.
###end p 61
###begin title 62
Immunoprecipitation and immunoblotting
###end title 62
###begin p 63
Cells were grown in 10- or 15-cm plates and lysed in 1% NP-40 buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 25 mM sodium beta-glycerophosphate, 1 mM sodium vanadate, 5 mM NaF, and complete protease inhibitors). A minimum of 1 mg of total cellular protein was incubated at 4degreesC overnight or for 3 h on a rotating wheel with antibody and complexes, and were then precipitated with 25 mul of protein G-Agarose (Thermo Fisher Scientific) for 20 min on a rotating wheel at 4degreesC. Beads were washed at least three times in 500 mul of lysis buffer and resuspended in NuPAGE LDS sample buffer before SDS-PAGE. Fluorescent immunoblotting was conducted using the Odyssey infrared scanner according to the manufacturer's protocols (Li-COR Biosciences). Fluorescence data from the Odyssey were exported into Excel. For phosphorylation analysis, signal from phosphospecific antibodies was divided by that of antibodies recognizing total protein (e.g., PY410/Total p130Cas). For p130Cas-Crk complexes, p130Cas signal was divided by Crk signal. For siRNA experiments in tumor cells, data were normalized to values from mock-transfected cells. For HEK 293T cells, data are presented as fold stimulation of phosphorylation, obtained by dividing the phospho/total ratio in uPAR-transfected cells by the vector control. In all cases, statistical comparisons for each siRNA were made against the nontargeting control, and ON-TARGET SMART Pools were compared with ON-TARGET nontargeting controls.
###end p 63
###begin title 64
Quantitative PCR
###end title 64
###begin p 65
###xml 398 399 390 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
Total cellular RNA was isolated from cultured cells using Trizol (Invitrogen) or the RNeasy Mini kit (QIAGEN). Real-time RT-PCR amplifications were performed using the Brilliant II SYBR Green QRT-PCR Master Mix kit (Stratagene). A standard curve was constructed using a range of 0.01 to 10 ng RNA from BE cells for each set of primers used. Relative quantitation was performed using the DeltaDeltaCt method. All primers used were Quantitect SYBR green primer assays (QIAGEN). Reactions were performed in triplicate in 50-mul volumes containing 25 mul of 2x Brilliant II mastermix, 5 mul of 10x Quantitect SYBR green primer assay, 1 mul of RT-RNase-block enzyme mixture (Stratagene), and the appropriate amount of RNA with remaining volume made up with nuclease-free water (Ambion). PCR was performed in a Fast Real-Time PCR cycler (7900HT; Applied Biosystems). Data were analyzed using SDS software (Applied Biosystems).
###end p 65
###begin title 66
Flow cytometry
###end title 66
###begin p 67
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 127 128 120 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 132 133 122 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 140 141 126 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 145 146 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 156 157 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 221 222 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 200 204 <span type="species:ncbi:9925">goat</span>
###xml 210 215 <span type="species:ncbi:10090">mouse</span>
Detached cells (5 x 106) were stained on ice for 45 min using 10 mug/ml LM609, 10 mug/ml P1F6, or 1 mug/ml P5D2 to detect alphavbeta3, alphavbeta5, and beta1, respectively. Alexa fluor 488-conjugated goat anti-mouse F(ab)2 fragment used for detection (at 1:250) was obtained from Invitrogen. Cells were analyzed on an LSR II flow cytometer (BD Biosciences).
###end p 67
###begin title 68
Adhesion assays
###end title 68
###begin p 69
###xml 58 82 58 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Cunningham et al. (2003)</xref>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 576 582 <span type="species:ncbi:9913">bovine</span>
Adhesion assays were performed according to the method of Cunningham et al. (2003). Cells were detached by short incubation with trypsin, counted, and washed in serum-free medium. 3 x 104 cells were allowed to adhere to 96-well plates (Thermo Fisher Scientific) precoated with 10 mug/ml fibronectin, 2 mug/ml vitronectin, or 10 mug/ml Type-I collagen for 30 min at 37degreesC. For blocking antibody studies, cells were preincubated with antibodies or control IgG (at 10 mug/ml) for 30 min before addition to the plate. Plates were washed three times in medium containing 0.2% bovine serum albumin (Sigma-Aldrich), fixed in formol saline, and stained with crystal violet. Staining was quantified by measuring absorbance at 540 nm using a SpectraMax M5 (Invitrogen) plate reader.
###end p 69
###begin title 70
Online supplemental material
###end title 70
###begin p 71
Fig. S1 shows a morphological screen of integrin-associated Rac GEFs. Fig. S2 shows siRNA-mediated knockdown of uPAR, DOCK180, p130Cas, Crk, and integrin subunits. Fig. S3 shows that uPAR-driven Rac activity in 293T cells requires beta3 integrin-dependent Src activation. Fig. S4 shows that silencing of beta integrin subunits in BE colon carcinoma cells affects cell morphology. Fig. S5 shows that uPAR-driven Rac activation is vitronectin dependent but adhesion to vitronectin requires alphavbeta3 or alphavbeta5, but not uPAR. Video 1 shows control BE colon carcinoma cells. Video 2 shows BE colon carcinoma cells transfected with siRNA-targeting uPAR. Video 3 shows BE colon carcinoma cells transfected with siRNA-targeting DOCK180. Online supplemental material is available at .
###end p 71
###begin title 72
Supplementary Material
###end title 72
###begin title 73
[Supplemental Material Index]
###end title 73
###begin p 74
We thank C. Isacke for helpful comments.
###end p 74
###begin p 75
This work was supported by Cancer Research UK and a Federation of European Biochemical Societies long-term fellowship to P. Marra. C.J. Marshall is a Gibb life fellow of Cancer Research UK.
###end p 75

